about
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptorMinipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in miceDose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice.Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey PharmacokineticsSynthesis of a cross-bridged cyclam derivative for peptide conjugation and 64Cu radiolabeling.Synthesis, characterization, and biological evaluation of integrin alphavbeta3-targeted PAMAM dendrimers.A novel side-bridged hybrid phosphonate/acetate pendant cyclam: synthesis, characterization, and 64Cu small animal PET imagingPreclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants.Effects of charge on antibody tissue distribution and pharmacokinetics.Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations.Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology.An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate.Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.Evaluation of Fluorophotometry to Assess the Vitreal Pharmacokinetics of Protein Therapeutics.Polyclonal antibodies to xenogeneic endothelial cells induce apoptosis and block support of tumor growth in mice.Comparative physiology of mice and rats: radiometric measurement of vascular parameters in rodent tissues.Vascular physiology and protein disposition in a preclinical model of neurodegeneration.Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands.Conjugation of monoclonal antibodies with TETA using activated esters: biological comparison of 64Cu-TETA-1A3 with 64Cu-BAT-2IT-1A3.Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes.Auger electrons: lethal, low energy, and coming soon to a tumor cell nucleus near you.Relative Target Affinities of T Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.Enhanced tumor retention of a radiohalogen label for site-specific modification of antibodies.Preclinical pharmacokinetic characterization of an adipose tissue-targeting monoclonal antibody in obese and non-obese animals.Development and evaluation of a novel method for preclinical measurement of tissue vascular volume.Validation of a novel CHX-A'' derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A''-octreotide.Antibody-mediated stabilization of NRG1 induces behavioral and electrophysiological alterations in adult mice.Tissue Physiology of Cynomolgus Monkeys: Cross-Species Comparison and Implications for Translational PharmacologyDynamics of protein-protein docking: cytochrome c and cytochrome c peroxidase revisitedHyaluronic Acid-Antibody Fragment Bioconjugates for Extended Ocular PharmacokineticsBiodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancerSite-specific conjugation allows modulation of click reaction stoichiometry for pretargeted SPECT imagingProduction, characterization, and in vivo half-life extension of polymeric IgA molecules in mice
P50
Q33301860-FECDEC93-7E33-4291-BCF1-69B8CE9EA6D9Q33573587-52FB8AF3-F2F9-4569-A4AF-7C4540D55653Q35992509-E7B053B2-2957-43A0-A29C-D3096CCD89D8Q36153295-F83F9D4B-FEBF-4BC9-994F-660276D041BDQ36213149-7EB543CE-5A52-404C-A6EC-814502BBF92FQ36215733-F515A5EE-BB93-4453-8F40-F1D3B9A99EF8Q36444225-C75A0501-97EF-403F-B397-033BA7009B8AQ36826058-21D27CC0-5A6E-416F-876C-9FB8439AFB86Q36952077-F1DA04E3-238E-4E04-9B6A-2E54749A9753Q37085287-D0B9991B-1AE3-47AE-9745-30D56D28BF0DQ37138952-ED3F78A1-9CA0-4F50-84DF-DAFE58E43C6CQ37576721-5D24A73D-4442-43CC-A432-B8A3C9353440Q37807394-25AA227C-720E-406C-811E-BAB9FAAF2EECQ38014786-D3331BA0-04B3-42ED-9C25-B18F61849902Q38028479-150FB3D2-89A4-4118-A010-C6A5B00CC9A6Q39298392-31F92954-8487-4546-854A-696BF2FF6F4FQ39300841-187E4C93-C2D4-4A89-ACF9-9BB5DDF7F45EQ39416858-03C975A1-B9BE-4FEA-B3BB-F60C3E5BEF2CQ40380005-7DADF718-6CB5-4B45-9C14-96B11431BC55Q42801877-DC0506B4-1196-4784-A01A-61DBC6BA1657Q43484240-DF2C509B-54B8-45C9-B324-6B53A86D38EBQ43649117-26875ED5-EC95-4B50-98CA-4AD2B2575DE9Q43849736-E057B7EF-5953-43AE-84FB-5D22559EA72BQ43853239-8602E4FF-C6C2-4AF5-9A8D-AD033463B1AEQ44784872-F20DFE25-73CD-4CF2-9AE8-A0927390D6DDQ46837683-32D10D3E-2CD2-479D-AFB0-3A544A761F2FQ48535042-0374F160-2D48-49C7-A38C-81BA6D230483Q48707322-10922D0D-D5FF-4363-9D89-D6A6F211F3A8Q50140611-7A856553-71F6-47F8-B86A-B491A71D6F16Q50565954-9B6BD0BF-E547-41A9-BFB5-002DA376A1BFQ53530705-2D7D1C0B-C379-4CA8-AE73-7ED25F8A06F4Q54967456-D86A25D9-03A7-43AA-A0C6-B974EB0DF226Q57292792-444D6383-B9D5-4033-AA71-36F92AA5BA66Q77618620-A890A2BB-2955-4428-B777-6A93E5BB618AQ90278818-F55B5D2F-9AC3-4B31-8436-55FBBD6BC804Q91141171-D42420EF-9C65-40DC-B5E0-4D5AD9CF80B6Q91356919-CA04CDC5-9755-4EEB-B75C-3B3A3984033FQ92248471-C3468E22-4AC4-4F0E-BA7E-CE1CD1FA57AC
P50
description
researcher
@en
name
C A Boswell
@en
C A Boswell
@nl
type
label
C A Boswell
@en
C A Boswell
@nl
prefLabel
C A Boswell
@en
C A Boswell
@nl
P106
P31
P496
0000-0002-0426-9846